Why does insulin cause sodium retention

Talor, D. View at: Google Scholar C. Rivera, H. Santos-Reyes, and M. View at: Google Scholar E. Feraille, M. Carranza, M. Rousselot, and H.

F55—F62, View at: Google Scholar O. Ruiz, YI. Qiu, L. Cardoso, and J. Ito, Y. Kondo, N. Takahashi et al. Takahashi, O. Ito, and K. S41—S45, Tsimaratos, F. Roger, D. Loffing and C. Blazer-Yost, X. Liu, and S. C—C, Rousselot, R. Rajerison, and H. Chibalin, M. Kovalenko, J. Ryder, E. Wallberg-Henriksson, and J. Lee, C. Campbell, D. Cook, and A. Loffing, S. Flores, and O. White, R.

Maron, and C. View at: Google Scholar X. Sun, P. Rothenberg, C. Kahn et al. Sun, L. Wang, Y. Zhang et al. Winnay, B. Cheatham, and C. Araki, M. Lipes, M. Patti et al. Kubota, K. Tobe, Y. Terauchi et al. View at: Google Scholar Y. Kido, D. Burks, D. Withers et al. Zheng, H. Yamada, K.

Sakamoto et al. Goodyear, F. Giorgino, L. Sherman, J. Carey, R. Smith, and G. Friedman, T. Ishizuka, J. Shao, L. Huston, T. Highman, and P. Rondinone, L. Wang, P. Lonnroth, C. Wesslau, J. Pierce, and U. Carvalho, P. Jansson, M. Axelsen et al. Al-Rasheed, G. Willars, and N. Wajant, K. Pfizenmaier, and P. Peraldi and B. Uysal, S. Wiesbrock, M. Marino, and G. Shoelson, J. Lee, and A. Amin, J. Malakooti, R. Sandoval, P. Dudeja, and K.

Amin, P. Dudeja, K. Ramaswamy, and J. G—G, Shahid, J. Francis, and D. DiPetrillo, B. Coutermarsh, and F. Coutermarsh, N. Soucy, J. Hwa, and F. Schmidt, K. Schweda, A. Kurtz, and M. Riquier-Brison, P. Leong, K. Pihakaski-Maunsbach, and A. El-Atat, S. Stas, S. Mcfarlane, and J. Velloso, F. Folli, L. Perego, and M. Lastra, S. Dhuper, M. Johnson, and J. Horita, Y. Zheng, C. Hara et al. Zheng, S. Horita, C. Yamada, Y. Kita et al.

Zhang, X. Chen, T. Hsieh et al. Xu, J. English, J. Wilsbacher, S. Stippec, E. Goldsmith, and M. Wilson, S.

Choate et al. McCormick, C. Yang, and D. Safar and H. Yang, J. Angell, R. Mitchell, and D. Golbang, G. Cope, A. Hamad et al. Cai, V. Cebotaru, Y. Ohta, T. Rai, N. Yui et al. Yang, X. Zhu, Z. Wang, A. Subramanya, and D. Subramanya, C. Zhu, and D. Rinehart, K. Kahle, P. De Los Heros et al. Heise, B.

Xu, S. Deaton et al. Vitari, M. Deak, B. Collins et al. Sohara, T. Rai, A. Ohta, e. Ohta, S. Sasaki, and S. Ellison, T. Oyama, C. Yang, S. Rogers, D. Beard, and R. SA-FC, November Huang and E. Hoorn, N. Van Der Lubbe, and R. View at: Publisher Site Google Scholar. More related articles. Download other formats More. Related articles. Both the glucose infusion rate and the insulin-induced glucose uptake into the muscle were found to be markedly decreased [ 13 ].

Thus, chronic administration of Ang II caused insulin resistance in the muscle and adipose tissues. In the Ang II-infused rats, the plasma level of lipid peroxide, a marker of oxidative stress, was also increased. Moreover, treatment with tempol, a membrane-permeable superoxide dismutase mimetic, reversed the Ang II-induced decrement in the glucose infusion rate in the evaluation using the hyperinsulinaemic—euglycaemic glucose clamp, and increased the glucose uptake in isolated skeletal muscle [ 13 ].

Thus, oxidative stress may play an important role in Ang II-induced insulin resistance. Indeed, it has been reported that Ang II-induced ROS up-regulation affects several levels of the intracellular insulin signalling pathways. Accordingly, treatment with blockers of RA system may improve insulin resistance, possibly through the inhibition of oxidative stress.

Infusion of Ang II has been shown to induce more severe insulin resistance in AM-deficient mice than in wild-type mice [ 17 ], suggesting antagonistic effects between endogenous AM and Ang II. Moreover, old, but not young, AM-deficient mice show insulin resistance in the muscle, possibly through overproduction of ROS [ 18 ], since oxidative stress might accumulate with advancing age. Lending support to this idea, treatment with tempol, an antioxidant, normalized the impaired glucose uptake by the muscle in both Ang II-infused rats [ 16 ] and old AM-deficient mice [ 18 ].

In AM-deficient mice, moreover, the administration of Ang II [ 16 ], hypoxia [ 19 ] and arterial cuff injury [ 20 ], all of which produce oxidative stress, was found to induce severe coronary arterial sclerosis, pulmonary arterial hyperplasia and arterial intimal hyperplasia, respectively. Taken together, in obese subjects with metabolic syndrome, imbalance in the production of several adipokines influencing insulin sensitivity may be involved in the development of insulin resistance, possibly through the overproduction of oxidative stress Figure 1.

There is a plausible hypothesis that insulin resistance plays a crucial role in the development of hypertension, diabetes and dyslipidaemia. Although the precise mechanism for insulin resistance-induced hypertension is still unknown, it has been hypothesized that while insulin resistance is observed in the muscle and adipose tissues, it is not seen in the kidney or the sympathetic nervous system.

Under this circumstance, since insulin can increase sodium reabsorption in the proximal tubules and stimulate sympathetic tone, hyperinsulinaemia increases the blood pressure by inducing salt retention and central sympathetic overactivity. This hypothesis is strengthened by our recent ex vivo study [ 3 ] using the proximal tubules of IRS and IRS deficient mice, in which while both mice showed insulin resistance and the resultant hyperinsulinaemia, only the former showed hypertension.

Administration of insulin probably increased the sodium reabsorption in the proximal tubules of the IRS-1 deficient mice, similar to that in the wild-type mice, by the activation of co-transport, but not in the proximal tubules of the IRS-2 deficient mice [ 3 ], suggesting that the renal action of insulin is mediated by IRS Consequently, IRS deficient mice showed higher blood pressure than IRS-2 deficient mice, possibly mediated by the greater sodium retention in the body.

Thus, insulin resistance in the muscle, which is attributable to derangements of IRS-1, induces glucose intolerance and dyslipidaemia; in turn, hyperinsulinaemia induces sodium retention via IRS-2 phosphorylation in the kidney, resulting in volume-dependent, salt-sensitive hypertension Figure 2. Lending support to this concept, the Olivetti Heart Study showed, using the lithium clearance method, that obese insulin-resistant subjects with metabolic syndrome showed a higher fractional sodium reabsorption in the proximal tubules [ 21 ].

Renal mechanism for hyperinsulinaemia-induced sodium retention in metabolic syndrome. In addition to hyperinsulinaemia, Ang II [ 22 ], which is generated from angiotensinogen produced by adipocytes, aldosterone, of which secretion is also stimulated by adipocytes [ 23 ], and the increased renal SNS activity [ 24 ], which is mediated by hyperinsulinaemia and hyperleptinaemia, can directly stimulate sodium reabsorption in the proximal and distal tubules Figure 3.

Furthermore, compression of the kidney by the huge abdominal fat mass might also influence tubular sodium reabsorption; the elevated interstitial hydrostatic pressure caused by compression could reduce medullary blood flow vasa recta and consequently increase sodium reabsorption in the ascending limb of the loop of Henle [ 25 ].

Taken together, all of these abnormalities might be involved in promoting sodium retention in the body Figure 3.

In fact, obese hypertensives show a more pronounced hypotensive response to salt restriction than non-obese hypertensives, but after they reduce their body weight, they also show a less pronounced salt-sensitivity of the blood pressure.

Thus, obese patients with metabolic syndrome often have salt-sensitive hypertension [ 26 ]. Conversely, salt-sensitive hypertension is characterized by the same features as those characterizing patients with metabolic syndrome, namely, obesity, insulin resistance, low serum HDL cholesterol, microalbuminuria, intraglomerular hypertension and high incidence of cardiovascular diseases [ 27 , 28 ]. The association of metabolic syndrome and salt-sensitive hypertension is thus not limited to obesity, and as both are associated with an unfavourable cardiovascular risk, there is also a considerable overlap of conditions that increase the cardiovascular risk as well.

Possible mechanism underlying the development of salt-sensitive hypertension and CKD in metabolic syndrome. Obese subjects with metabolic syndrome often exhibit microalbuminuria, CKD and non-dipping hypertension [ 1 , 29 , 30 ], which are all independent risk factors for cardiovascular disease.

The appearance of microalbuminuria might be attributable to glomerular hyperfiltration [ 31 ]. According to the reported mechanism of occurence of intraglomerular hypertension, increased tubular sodium reabsorption in the proximal tubules and loop of Henle reduces the macula densa NaCl delivery [ 32 ], which leads to a feedback-mediated vasodilatation of the afferent arterioles, elevation of the glomerular filtration rate and stimulation of the RA system, despite the volume expansion Figure 3.

These compensatory responses are aimed at overcoming the increased tubular reabsorption and maintaining the sodium balance [ 25 ]. However, persistent glomerular hyperfiltration also causes proteinuria and CKD.

In addition to the renal haemodynamics, adipocyte-related humoral factors may also be involved in the occurrence of albuminuria and CKD. Some investigators have demonstrated that aldosterone-releasing factors are produced by adipocytes [ 23 ]. Consistent with this, plasma aldosterone concentrations are increased in obese subjects with metabolic syndrome [ 33 ].

Hyperaldosternism induces sodium retention in the body by the increased sodium reabsorption in the distal and collecting tubules, resulting in salt-sensitive hypertension. Moreover, we have recently showed that mineralcorticoid receptor MR is present not only in the tubular cells but also glomerular podocytes; the hyperaldosteronism-induced MR activation might induce glomerular podocyte injury to cause proteinuria in obese hypertensive rats with metabolic syndrome, possibly through the overproduction of ROS [ 34 ].

Moreover, salt loading aggravates podocyte injury and proteinuria markedly in these obese hypertensive rats, associated with increased MR-dependent gene expressions. It is well known that salt and aldosterone have an unfavourable synergistic action on the cardiovascular system since the administration of aldosterone induces severe cardiac damages in rats on a high-salt diet, but does not affect it in those on a low-salt diet [ 35 ].

However, the treatment of eplerenone, a selective aldosterone receptor blocker, was shown to dramatically reduce the podocyte injury and proteinuria in obese hypertensive rats, even those on a high-salt diet [ 34 , 36 , 37 ]. Accordingly, PREVEND study shows that salt intake affects urinary albumin excretion especially in overweight subjects [ 38 ], although plasma aldosterone was not measured. Thus, changes in renal haemodynamics and humoral factors can induce progressive renal failure in metabolic syndrome.

In turn, impaired renal function in relation to sodium excretion increases the salt-sensitivity of blood pressure Figure 3. There is an intimate relationship between salt-sensitivity and insulin sensitivity in hypertensive patients [ 4—7 ]. Accordingly, a high-salt diet not only increases the blood pressure, but also decreases the insulin sensitivity in Dahl salt-sensitive rats [ 39 ]. However, treatment with tempol, an antioxidant, normalized the salt-induced insulin resistance, suggesting that salt-induced insulin resistance might be attributable to the overproduction of ROS.

Accordingly, the Finnish epidemiological study showed that the prevalence of diabetes was higher among obese, but not lean, people on a high-salt diet [ 40 ]. In contrast to sodium, potassium possesses antihypertensive [ 41 , 42 ] and anti-oxidant effects [ 39 ].

Potassium supplementation not only attenuated salt-induced elevation of blood pressure [ 41 , 42 ], but also improved salt-induced insulin resistance [ 39 ] in salt-sensitive hypertensive patients and animals, associated with the normalization of ROS overproduction, suggesting that it inhibits salt-induced ROS overproduction.

Consistent with this, the DASH diet, consisting of vegetables and fruits rich in potassium, which could lower lipid-induced oxidative stress in obesity [ 43 ], decreased not only blood pressure, but also the fasting blood sugar in hypertensive patients [ 44 ]. Thus, dietary potassium can counteract the effects of dietary sodium to increase the insulin sensitivity in patients with salt-sensitive hypertension, possibly through decreasing the production of reactive oxygen species Figure 1.

Moreover, in Dahl salt-sensitive rats, a high salt intake induced cardiac diastolic dysfunction, because of increased ROS production in the heart, but potassium supplementation could reverse this abnormality through the inhibition of ROS production [ 45 ]. Thus, dietary salt and potassium stimulate and inhibit ROS production, respectively Figure 1 ; in turn, overproduction of ROS might induce not only insulin resistance, but also cardiac dysfunction and atherosclerosis in salt-sensitive hypertensive humans and animals.

In support of this suggestion, potassium supplementation could reduce the incidence of stroke in salt-loaded Dahl salt-sensitive rats, independent of the blood pressure [ 46 ]. Treatment with antioxidants is also effective in inhibiting salt-induced cardiac and renal damage in Dahl salt-sensitive hypertensive rats [ 45 , 47 ].

Taken together, ROS might play a critical role not only in the development of insulin resistance and salt-sensitive hypertension, but also in that of salt-induced cardiovascular damage in patients of salt-sensitive hypertension with metabolic syndrome [ 48 ].

Therefore, salt restriction and dietary intake of fruits and vegetables rich in potassium should be prescribed as a first-line lifestyle therapy for patients with metabolic syndrome, together with physical exercise, with the goal of improving the obesity-associated risk profile, such as insulin resistance and salt-sensitive hypertension Figure 1. Finally, it is evident that there are several endogenous and exogenous factors that can influence insulin sensitivity.

Not only adipokines released from visceral fat but also salt from processed foods can induce insulin resistance in the muscle and adipose tissues, through the overproduction of oxidative stress. Based upon the lack of insulin resistance in the kidney, however, hyperinsulinaemia causes sodium retention by stimulating sodium reabsorption in the proximal tubules. In addition, increased Ang II, increased aldosterone and reduced medullary flow by visceral fat-induced compression of the kidney might also be involved in the increased sodium reabsorption in the proximal and distal tubules, promoting sodium retention, and consequently, inducing salt-sensitive hypertension Figure 3.

Not only chronic glomerular hypertension but also hyperaldosteronism might induce proteinuria and CKD. Taken together, patients with metabolic syndrome are often associated with salt-sensitive hypertension and CKD. Therefore, salt restriction is important for obese patients with metabolic syndrome to prevent CKD, since salt restriction is effective in improving not only salt-sensitive hypertension but also insulin resistance.

Google Scholar. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation.

Volume Article Contents Introduction. Insulin resistance in metabolic syndrome. Angiotensin and insulin resistance. The mechanism for salt-sensitive hypertension in metabolic syndrome. CKD in metabolic syndrome. Role of salt and potassium in metabolic syndrome. Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Toshiro Fujita Toshiro Fujita. Oxford Academic. Select Format Select format. Permissions Icon Permissions. Open in new tab Download slide. Mechanism for insulin resistance in metabolic syndrome.